TP联合替吉奥胶囊对中晚期食管癌患者的临床疗效及血清VEGF、VEGFR-1的影响

Clinical curative effect of TP combined with S-1 capsules on patients with middle and late esophageal cancer and their influences on serum VEGF and VEGFR-1

目的:探讨TP化疗方案联合替吉奥胶囊对中晚期食管癌患者的临床疗效。方法:选取确诊为晚期食管癌的80例患者作为研究对象,随机均分为观察组与对照组,每组各40例。对照组采用TP化疗,观察组采用TP化疗联合替吉奥胶囊口服治疗,比较两组患者临床疗效,治疗前后血管内皮因子(VEGF)、血管内皮因子受体(VEGFR-1)水平,毒副反应发生情况、生存质量以及1年内无进展生存率。结果:观察组总有效率为75.0%,对照组总有效率为47.5%,差异比较有统计学意义(P<0.05);治疗后观察组VEGF、VEGFR-1水平明显低于对照组(P<0.05);观察组毒副反应发生率为42.5%,对照组毒副反应发生率为57.5%,差异有统计学意义(P<0.05);治疗后,观察组生命质量QLQ-C30评分优于对照组(P<0.05);对照组1年无进展生存率为50.0%,观察组1年无进展生存率为72.5%,差异有统计学意义(P<0.05)。结论:TP化疗联合替吉奥胶囊治疗能够显著提高中晚期食管癌患者的无进展生存期及生命质量,降低VEGF、VEGF-1水平,毒副作用小,临床疗效良好。

Objective:To explore the clinical curative effect of TP chemotherapy regimen combined with Tegafur,Gimeracil and Oteracil Porassium(S-1)capsules on patients with middle and late esophageal cancer.Methods:80 patients who were confirmed with advanced esophageal cancer were enrolled as the research objects.They were randomly and averagely divided into observation group and control group,and 40 cases in each group.The control group was treated with TP chemotherapy,while observation group was treated with TP chemotherapy combined with oral S-1 capsules.The clinical curative effect,levels of vascular endothelial growth factor(VEGF)and vascular endothelial growth factor receptor-1(VEGFR-1)before and after treatment,incidence of toxic and side effects,quality of life and progression-free survival(PFS)rate within 1 year were compared between the two groups.Results:The total response rate in observation group was significantly higher than that in control group(75.0%vs.47.5%),the difference was statistically significant(P<0.05).After treatment,levels of VEGF and VEGFR-1 in observation group were significantly lower than those in control group(P<0.05).There was significant difference in incidence of toxic and side effects between observation group and control group(42.5%vs.57.5%,P>0.05).After treatment,the score of QLQ-C30 in observation group was superior to that in control group(P<0.05).There were significant differences in 1-year progression free survival(PFS)rate between control group and observation group(50.0%vs.72.5%,P<0.05).Conclusion:TP chemotherapy combined with capsules can significantly improve PFS and quality of life in patients with middle and late esophageal cancer,reduce levels of VEGF and VEGF-1,with few toxic and side effects and good clinical curative effect.